Titre :

Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative proctitis

Auteur(s) :

Pineton De Chambrun, Guillaume [Auteur]
Université de Montpellier [UM]
Amiot, Aurelien [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Bouguen, Guillaume [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]
Viennot, Stephanie [Auteur]
CHU Caen
Altwegg, Romain [Auteur]
Université de Montpellier [UM]
Louis, Edouard [Auteur]
Collins, Michael [Auteur]
Fumery, Mathurin [Auteur]
Service d'Hépato Gastroenterologie [CHU Amiens-Picardie]
Poullenot, Florian [Auteur]
Université de Bordeaux [UB]
Armengol-Debeir, Laura [Auteur]
CHU Rouen
Buisson, Anthony [Auteur]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Abitbol, Vered [Auteur]
Université Paris Descartes - Paris 5 [UPD5]
Laharie, David [Auteur]
Université de Bordeaux [UB]
Seksik, Philippe [Auteur]
Assistance publique - Hôpitaux de Paris (AP-HP) [AP-HP]
Nancey, Stephane [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Blanc, Pierre [Auteur]
Université de Montpellier [UM]
Bouhnik, Yoram [Auteur]
Pariente, Benjamin [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Peyrin-Biroulet, Laurent [Auteur]
Université de Nancy

Titre de la revue :

Clinical Gastroenterology and Hepatology

Nom court de la revue :

Clin. Gastroenterol. Hepatol.

Numéro :

18

Pagination :

620-627.e1

Date de publication :

2020-03

ISSN :

1542-7714

Mot(s)-clé(s) en anglais :

Inflammatory Bowel Disease
Proctitis
Trial
Immune Suppression
Second-Line Treatment

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

It is a challenge to manage patients with ulcerative proctitis (UP) refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a large cohort of patients with refractory ...
Lire la suite >It is a challenge to manage patients with ulcerative proctitis (UP) refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a large cohort of patients with refractory UP. We conducted a nationwide retrospective cohort study of 104 consecutive patients with active UP refractory to conventional therapies, treated at 1 of 15 centers in France or 1 center in Belgium (the GETAID cohort). Patients received at least 1 injection of anti-TNF (infliximab, adalimumab, golimumab) from October 2006 through February 2017. Clinical response was defined as significant improvement in UC-related symptoms, and remission as complete disappearance of UC-related symptoms, each determined by treating physicians. We collected demographic, clinical, and treatment data. The median duration of follow-up was 24 months (interquartile range, 13-51 months). The primary outcome was clinical response of UP to anti-TNF treatment. Overall, 80 patients (77%) had a clinical response to anti-TNF therapy and 52 patients (50%) achieved clinical remission. Extra-intestinal manifestations (odds ratio OR, 0.24; 95% CI, 0.08-0.7), ongoing treatment with topical steroids (OR, 0.14; 95% CI, 0.03-0.73), and ongoing treatment with topical 5-aminosalycilates (OR, 0.21; 95% CI, 0.07-0.62) were significantly associated with the absence of clinical remission. Sixty percent (38/63) of the patients who had endoscopic assessment during follow up had mucosal healing. Among the overall population (n = 104), the cumulative probabilities of sustained clinical remission were 87.6% ± 3.4% at 1 year and 74.7% ± 4.8% at 2 years. In a retrospective study of 104 patients with refractory UP, anti-TNF therapy induced clinical remission in 50% and mucosal healing in 60%. About two thirds of the patients were still receiving anti-TNF therapy at 2 years.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-30T10:28:22Z
2024-04-25T08:38:48Z